clinical topic updates by Corey Cutler, MD, MPH, FRCP(C)
The manifestations and severity of chronic graft-versus-host disease (cGVHD) are highly variable and are influenced by cytokines and downstream pat......READ MORE
expert roundtables by Jeremy S. Abramson, MD, MMSc; Brad Kahl, MD; and Matthew J. Matasar, MD
Several newer therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are now available, and other agents that are under invest......READ MORE
The optimal management of double-hit relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) continues to be a challenge, with limited data t......READ MORE
patient care perspectives by Matthew J. Matasar, MD
The risk of recurrence, growth, and spread of gastrointestinal stromal tumors (GIST) after surgery relates to key variables such as the size, locat......READ MORE
patient care perspectives by Matthew J. Matasar, MD
Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who do not proceed to autologous hematopoietic stem cell transplantatio......READ MORE
patient care perspectives by Jeremy S. Abramson, MD, MMSc
In relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), cure is a possibility even in the second and third line. For those who cannot pro......READ MORE
expert roundtables by Daniel R. Couriel, MD, MS; Corey Cutler, MD, MPH, FRCP(C); and Sergio A. Giralt, MD
A major recent development in chronic graft-versus-host disease (cGVHD) has been the emergence of novel treatments that more precisely target the d......READ MORE
